6 Houston health tech startups making major advancements right now

meet the finalists

Tatiana Fofanova and Dr. Desh Mohan, founders of Koda Health. Photo courtesy Koda Health.

Home to leading hospitals, universities and health-focused incubators, Houston is a breeding ground for innovative medical technology and breakthroughs that can improve outcomes and lead to a better quality of life for patients.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Six forward-thinking businesses have been named finalists for the 2025 award. They range from an end-of-life care company to others developing devices and systems for heart monitoring, sleep apnea, hearing loss and more.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below. Then join us at the Houston Innovation Awards on Nov. 13 at Greentown Labs, when the winner will be unveiled at our live awards ceremony.

Tickets are now on sale for this exclusive event celebrating all things Houston Innovation.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient. The system is currently in the research and development phase and is being used in clinical trials and studies.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. It raised a pre-seed round last year of $435,000.

Corveus Medical

Corveus Medical has developed a novel catheter device that allows cardiologists to perform a splanchnic nerve ablation, restoring the pressure balance in patients with moderate heart failure. Its pre-FDA-approved, minimally invasive solution deactivates a nerve that has been demonstrated to be a root cause behind heart failure progression, which allows physicians to treat patients who have traditionally had few options.

The company, formerly known as Caridian Medical, was founded in 2021 by CEO Tyler Melton and CMO Ishan Kamat. It has participated in incubators such as TMC Biodesign, Y Combinator, MedTech Innovator and Fogarty Innovation and was named one of the 10 most promising life science companies at Texas Life Science Forum in 2022. The company says it will move toward validation and verification testing for its device in Q4 of this year.

FibroBiologics

Regenerative medicine company FibroBioligics uses fibroblasts, the body’s most common type of cell, rather than stem cells, to help grow new cells to repair tissue and modulate the immune system. The cell therapies offer treatments for chronic conditions such as degenerative disc disease, multiple sclerosis and non-healing wounds.

The publicly traded company was founded in 2021 by CEO Pete O'Heeron. It opened a new 10,000-square-foot Houston lab earlier this year to scale up research efforts and pave the way for in-house manufacturing. The company says it plans to launch its first clinical trial for diabetic foot ulcers soon, representing the transition of its fibroblast technology to the clinic setting.

Koda Health

Koda Health has developed an advance care planning platform (ACP) that allows users to document and share their care preferences, goals and advance directives for health systems. The web-based platform guides patients through values-based decisions with interactive tools and generates state-specific, legally compliant documents that integrate seamlessly with electronic health record systems. The company also added kidney action planning to its suite of services for patients with serious illnesses last year.

Koda Health was founded out of the TMC's Biodesign Fellowship in 2020 by CEO Tatiana Fofanova, chief medical officer Dr. Desh Mohan, and chief technology officer Katelin Cherry. The company raised a $7 million series A earlier this year, and also announced major partnerships and integrations with Epic, Guidehealth, Medical Home Network, Privia Health and others.

NanoEar

NanoEar has miniaturized hearing aid technology so that it can be implanted across the eardrum, allowing adults with age-related hearing loss to enjoy better sound quality than they would with behind-the-ear hearing aids.

Dr. Ron Moses, an ENT specialist and surgeon at Houston Methodist, developed the technology, and the company was founded in 2016 with CFO Willem Vermaat and COO Michael Moore. The company participated in the TMC Innovation Institute in 2016. It has issued nine U.S. patents and performed successful human cadaver and animal proof-of-concept experiments. Its next step is developing a prototype.

Wellysis USA

Wellysis USA Inc. works to detect heart rhythm disorders with its continuous ECG/EKG monitor with AI reporting. Its S-Patch cardiac monitor is designed for extended testing periods of up to 14 days on a single battery charge. The device weighs only 9 grams, is waterproof and designed to be comfortable to wear, and is considered to have a high detection rate for arrhythmias. It is ideally suited for patient-centric clinical trials to help physicians make diagnoses faster, cheaper and more conveniently.

It was established in Houston in 2023 and participated in the JLABS SFF Program the same year. It closed a $12 million series B last year. It was founded by CEO Young Juhn, CTO Rick Kim, CFO JungSoo Kim and chief strategy officer JoongWoo Kim.

---

The Houston Innovation Awards program is sponsored by Houston City College Northwest, Houston Powder Coaters, FLIGHT by Yuengling, and more to be announced soon. For sponsorship opportunities, please contact sales@innovationmap.com.

From Your Site Articles
Three Houston-based health tech companies were announced to have joined the 2022 cohort of MedTech Innovator. Photo via Getty Images

3 Houston health tech companies join global accelerator cohort

Three Houston-based medtech startups are getting a big boost from a medtech accelerator.

The startups — Ad Vital, Corveus Medical, and CorInnova — have been chosen from this year’s cohort for MedTech Innovator, an international accelerator that helps companies that created health care technology. In all, 55 startups are involved in this year’s four-month accelerator program.

Ad Vital and Corveus Medical also are participating in MedTech Innovator’s corporate mentorship program, while CorInnova is one of five startups picked for the pediatric accelerator track.

MedTech Innovator’s 10th annual program kicked off in mid-June at the MedTech Innovator Summit in Mountain View, California. Leaders from each of the 50 startups attended networking events and workshops with MedTech Innovator partners and other industry professionals. Members of this year’s cohort also were featured June 17 at the WSGR Medical Device Conference in San Francisco.

Only 5 percent of applicants were accepted for this year’s accelerator program. Earlier this year, MedTech Innovator held in-person pitch events in five cities, including Houston.

At the conclusion of the 2022 program, MedTech Innovator will award $500,000 in cash and in-kind prizes at this October’s MedTech Conference in Boston. The grand prize is $350,000.

“Over the past nine years, MedTech Innovator has established a unique track record of identifying and supporting leading startups, with 95 percent of our graduates either still in business or having been acquired,” Paul Grand, CEO of MedTech Innovator, says in a news release.

Here’s an overview of what Ad Vital, Corveus Medical, and CorInnova do:

  • Ad Vital’s app helps medical practices through sales, marketing, and operations. For instance, the app automatically organizes sales campaigns aimed at converting customer leads via text messages, emails, and Facebook messages.
  • Corveus Medical’s catheter device is designed to prevent heart failure. More than 6 million American adults experience heart failure. The company is also among five selected to pitch in October for a competition from the National Capital Consortium for Pediatric Device Innovation.
  • CorInnova’s minimally invasive device is engineered to treat congestive heart failure, particularly infants. Each year, about 10,000 babies born in the U.S. have critical heart defects that often require surgery or other procedures.
Houston's medical innovation community congregated to discuss breakthrough innovations in health care. Photo via Getty Images

Houston organizations announce 10 most promising life science startups

future of health care

What startups are creating the future of health care? A Houston conference this week gathered to discuss.

The 10th annual Texas Life Science Forum hosted by BioHouston and the Rice Alliance for Technology and Entrepreneurship engaged thought leadership within the life science community with panels, discussions, and more. Additionally, 49 companies pitched their solutions across medical device, therapeutics, pharmaceuticals, and more to the crowd.

Austin-based Dynamic Light won the Michael E. DeBakey Memorial Life Science Award, established by BioHouston in honor of the groundbreaking Houston cardiovascular surgeon. The software company integrates with microscope or robotic systems to provide better visuals to surgeons and health care providers and reduce medical errors, radiation and costs. The award was presented by Ann Tanabe, CEO of BioHouston.

The event also named the 10 most promising life science companies selected by investors and presented by the Greater Houston Partnership. This year's selection included the following companies, in alphabetical order.

Ares Immunotherapy

Photo via Getty Images

Based in Cartersville, Georgia, Ares Immunotherapy uses a unique subset of T-cells for the treatment of solid tumors. According to the company, it is is preparing for a first in man trial in mesothelioma in 2023.

Corveus Medical

Photo courtesy of TMC

Houston-based Corveus Medical, which was formerly known as Caridian Medical, is a part of TMC's Biodesign program. The company was founded by Ishan Kamat, COO, and Tyler Melton, CEO.

"We are developing a novel, catheter-based device that performs a targeted sympathetic nerve ablation to treat heart failure," according to the company. "Our solution leverages the body’s natural mechanisms to bring fluid levels back to normal, giving physicians an effective treatment option, reducing costs for hospitals, and improving quality of life for the patient."

Drusolv Therapeutics

Photo via Pexels

Drusolv Therapeutics, based in Philadelphia, Pennsylvania, was founded out of Harvard University and been validated in a proof-of-concept clinical trial. The company's product, a novel reformulation of atorvastatin, is targeting age-related macular degeneration, or AMD, a serious eye disease. According to the company, it's a $4 billion a year, unmet need.

EMPIRI

Photo via jlabs.jnjinnovation.com

Houston-based EMPIRI is an early-stage biotechnology company currently focusing on precision oncology and utilizing automation for personal diagnosis. The company works out of JLABS @ TMC.

"Our proprietary 3D tissue culture method, E-slices, enables personalized drug response measurements from intact patient tissues," per the company. "E-slice has been clinically validated to accurately predict individual cancer patient responses to chemotherapies, targeted therapies, a immunotherapies."

Lapovations

Photo via Getty Images

Based in Fayetteville, Arkansas, Lapovations is working on technologies that improve laparoscopy.

"Our flagship product AbGrab is a single-use device that uses suction to lift the abdominal wall prior to closed insertion entry," according to the company. "Manually lifting can be difficult and unreliable, especially with obese patients or for clinicians with small hands."

Maxwell Biosciences

Photo by Chokniti Khongchum from Pexels

Austin-based Maxwell Biosciences is creating anti-infectives that inactivate a broad spectrum of viruses. The company's product, CLAROMERS, has seen success in its preclinical animal studies, as well as lab-grown human tissues. Maxwell is fueled by over $30 million in non-dilutive and government funding (e.g. DARPA, NIH, NIAID).

NeuraStasis

Image via neurastasis.com

Doctors have to respond quickly when treating ischemic stroke patients, and Houston-based NeuraStasis is working on a way to give them more time. Each minute a patient is waiting, irreparable damage is being done. The company's noninvasive solution uses electrical neurostimulation to preserve brain functionality. NeuraStasis is based in JLABS @ TMC.

Vena Medical

Image via venamed.ca

Canada medical device company Vena Medical is working on the "world's smallest camera" that is able to record inside veins and arteries to help physicians treat stroke.

Vivifi Medical

Photo courtesy of TMC

Houston-based Vivifi Medical, a Texas Medical Center Innovation company, is working to improve the quality of life of patients with Male Infertility and benign prostatic hyperplasia — 12 million men in the United States alone — by ending recurrency via suture-less laparoscopic technology.

XN Health

Image via xn-health.com

XN Health, based in Houston, has developed a novel approach to phrenic nerve stimulation to treat progression of ventilator induced diaphragm disfunction to help wean patients off the ventilator faster. The technology should speed up patient liberation times, shortening ICU stay, improve healthcare outcomes, and reduce health care costs.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

5 Houston-area companies named among world's most innovative for 2026

In The Spotlight

Led by Conroe-based Hertha Metals, five organizations in the Houston area earned praise on Fast Company’s list of the World’s Most Innovative Companies of 2026.

Hertha Metals ranked No. 1 in the manufacturing category.

Last year, Hertha unveiled a single-step process for steelmaking that it says is cheaper, more energy-efficient and just as scalable as traditional steel manufacturing. It started testing the process in 2024 at a one-metric-ton-per-day pilot plant.

At the same time, Hertha announced more than $17 million in venture capital funding from investors such as Breakthrough Energy, Clean Energy Ventures, Khosla Ventures, and Pear VC.

“We’re not just reinventing steelmaking; we’re redefining what’s possible in materials, manufacturing, and national resilience,” Laureen Meroueh, founder and CEO of Hertha, said at the time.

Meroueh was also recently named to Inc. Magazine's 2026 Female Founders 500 list.

Hertha, founded in 2022, says traditional steelmaking relies on an outdated, coal-based multistep process that is costly, and contributes up to 9 percent of industrial energy use and 10 percent of global carbon emissions.

By contrast, Hertha’s method converts low-grade iron ore into molten steel or high-purity iron in one step. The company says its process is 30 percent more energy-efficient than traditional steelmaking and costs less than producing steel in China.

Last year, Hertha said it planned to break ground in 2026 on a plant capable of producing more than 9,000 metric tons of steel per year. In its next phase, the company plans to operate at 500,000 metric tons of steel production per year.

Here are Fast Company’s rankings for the four other Houston-area organizations:

  • Houston-based Vaulted Deep, No. 3 in catchall “other” category.
  • XGS Energy, No. 7 in the energy category. XGS’ proprietary solid-state geothermal system uses thermally conductive materials to deliver affordable energy anywhere hot rock is located. While Fast Company lists Houston as XGS’ headquarters, and the company has a major presence in the city, XGS is based in Palo Alto, California.
  • Houston-based residential real estate brokerage Epique Realty, No. 10 in the business services category. Epique, which bills itself as the industry’s first AI brokerage, provides a free AI toolkit for real estate agents to enhance marketing, streamline content creation, and improve engagement with clients and prospects.
  • Texas A&M University’s Nanostructured Materials Lab in College Station. The lab studies nano-structured materials to make materials lighter for the aerospace industry, improve energy storage, and enable the creation of “smart” textiles.
---

This article first appeared on our sister site, EnergyCapitalHTX.com.

UH lands $11.8M for first-of-its-kind early language development study

speech funding

Researchers at the University of Houston have secured an $11.8 million grant from the National Institutes of Health to conduct a first-of-its-kind study of early language development.

Led by Elena Grigorenko, the Hugh Roy and Lillie Cranz Cullen Distinguished Professor of Psychology, and research professor Jack Fletcher, the study will follow 3,600 children aged 18 to 24 months to uncover how language skills develop at this critical stage and why some children experience delays that can influence later growth.

The NIH funding will also support the development of the new national Clinical Research Center on Developmental Language Disorders at UH, which aims to bring experts from psychology, education, health and measurement sciences to study how children learn language.

“This will be the first national study to estimate how common late talking is using a large, representative sample of Houston toddlers,” Grigorenko said in a news release. “By following these children as they grow, we hope to better understand the developmental pathways that can lead to conditions such as developmental language disorder and autism.”

UH’s team will partner with the pediatric clinic network at Texas Children’s Hospital, where children will be screened for early language development, allowing researchers to identify those who show signs of delayed speech. Next, researchers will follow the cohort through early childhood to examine how language abilities evolve and how early delays may lead to later challenges.

The Clinical Research Center on Developmental Language Disorders will be the 14th national research center established at UH, and will include researchers from multiple UH departments, as well as partners at Baylor College of Medicine and the Texas Center for Learning Disorders.

“This level of investment from the National Institutes of Health reflects the significance of this work to address a complex challenge affecting children, families and communities,” Claudia Neuhauser, vice president for research at UH, said in a news release. “By bringing together experts from multiple disciplines and partnering with major health systems across the region, the project reflects our commitment to advancing discoveries that impact our community.”

Rice Alliance names Houston healthtech exec as first head of platform

new hire

The Rice Alliance for Technology and Entrepreneurship has named its first head of platform.

Houston entrepreneur Laura Neder stepped into the newly created role last month, according to an email from Rice Alliance. Neder will focus on building and growing Houston’s Venture Advantage Platform.

The emerging platform, which is being promoted by Rice Alliance and the Ion, aims to connect founders with the "people, capital and expertise they need to scale."

"I’ve spent a lot of time thinking about what it takes to make an innovation ecosystem more navigable, more connected, and more useful for founders," Neder said in a LinkedIn post. "I’m grateful for the opportunity to do that work at Rice Alliance, alongside a team with a long history of supporting entrepreneurship and innovation."

"Houston has the talent, institutions, and industry base to create real advantage for founders," she added. "I’m looking forward to listening, learning, and building stronger pathways across the ecosystem."

Neder most recently served as CEO of Houston-based Careset, where she helped bring the Medicare data startup to commercialization. Prior to that, Neder served as COO of Houston-based telemedicine startup 2nd.MD, which was acquired for $460 million by Accolade in 2021.

"Laura brings a rare combination of founder empathy, operational experience and ecosystem leadership," Rice Alliance shared.

Neder and Rice Alliance also shared that the organization is hiring developers to design the new Venture Advantage Platform. Learn more here.

View All Listings